Fenofibrate NDC 68071-2369

NDC codes

FDA NDC Directory

Product NDC (as listed)68071-2369Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68071-2369Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68071-2369-9	68071236909	90 TABLET, COATED in 1 BOTTLE (68071-2369-9)Marketed from Mar 17, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibrate
Generic name (nonproprietary): fenofibrate
Active ingredients: Fenofibrate — 48 mg/1
Dosage form: Tablet, Coated
Route: Oral
Labeler: NuCare Pharmaceuticals,Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205118
Marketing start: May 5, 2016
Listing expires: Dec 31, 2027
Identifiers: Product ID 68071-2369_4b45622d-5001-33a3-e063-6394a90afb6eSPL ID 4b45622d-5001-33a3-e063-6394a90afb6eSPL set ID bdc2211e-6d65-1500-e053-2a95a90ab145RxCUI 477562UNII U202363UOSUPC 0368071236996
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468071236909 followed by a unit qualifier and the quantity

Package 68071-2369-09. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 20, 2026.

Indications (excerpt from the label)

Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (To…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205118

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205118
Product	Strength	Form · route	Labeler	Product NDC
Fenofibrate	Fenofibrate 145 mg/1	Tablet, CoatedOral	QUALLENT PHARMACEUTICALS HEALTH LLC	82009-060
Fenofibrate	Fenofibrate 48 mg/1	Tablet, CoatedOral	Aurobindo Pharma Limited	65862-768
Fenofibrate	Fenofibrate 145 mg/1	Tablet, CoatedOral	Aurobindo Pharma Limited	65862-769
Fenofibrate	Fenofibrate 48 mg/1	Tablet, CoatedOral	A-S Medication Solutions	50090-3887
Fenofibrate	Fenofibrate 48 mg/1	Tablet, CoatedOral	Bryant Ranch Prepack	71335-1701